Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition

A computer system for qualifying a human subject for over-the-counter delivery of an angiotensin II receptor blocker pharmaceutical composition for lowering blood pressure, the computer system comprising one or more processors and a memory, the memory comprising non-transitory instructions which, when executed by the one or more processor, cause the computer system to perform a method comprising:

• a) conducting an assessment survey of the subject thereby obtaining a plurality of assessment survey results, wherein the plurality of assessment survey results comprises:
• whether the subject is one of (i) pregnant, (ii) breastfeeding, or (iii) planning to become pregnant,
• whether the subject is taking a medication that interacts with the angiotensin II receptor blocker pharmaceutical composition,
• a systolic blood pressure of the subject,
• a diastolic blood pressure of the subject,
• an age of the subject,
• information required to calculate a risk of atherosclerotic cardiovascular disease for the subject,
• whether the subject has ever had an abnormal electrolyte blood level, and
• whether the subject has ever had a kidney problem;
• b) running all or a portion of the plurality of assessment survey results against a first plurality of assessment filters of a first category class, wherein, when a respective filter in the first plurality of assessment filters is fired, the subject is deemed not qualified for delivery of the angiotensin II receptor blocker pharmaceutical composition and the method is terminated without delivery of the angiotensin II receptor blocker pharmaceutical composition to the subject, wherein the first plurality of assessment filters comprises:
• a pregnancy assessment filter that is fired at least when the plurality of assessment survey results indicates that the subject is pregnant or the subject is breastfeeding,
• a drug interaction assessment filter that is fired at least when the plurality of assessment survey results indicate that the subject is taking a medication that interacts with the angiotensin II receptor blocker pharmaceutical composition,
• a blood pressure assessment filter that is fired at least when the plurality of assessment survey results indicates the subject is not hypertensive or the subject has severe hypertension,
• an age assessment filter that is fired at least when the plurality of assessment survey results indicate the subject is too young to receive the angiotensin II receptor blocker pharmaceutical composition, and
• a pooled cohort equation assessment filter that is fired at least when the plurality of assessment survey results indicate that the subject has a risk for atherosclerotic cardiovascular disease that is below a floor threshold of risk or the subject has an incalculable risk for atherosclerotic cardiovascular disease;
• c) running all or a portion of the plurality of assessment survey results against a second plurality of assessment filters of a second category class, wherein, when a respective filter in the second plurality of assessment filters is fired, the subject is provided with a warning corresponding to the respective filter, and wherein the second plurality of assessment filters comprises:
• an electrolyte blood level assessment filter that is fired at least when the plurality of assessment survey results indicates that the subject has had an abnormal electrolyte blood level, and
• a kidney problem assessment filter that is fired at least when the plurality of assessment survey results indicates that the subject has had a kidney problem,
• d) obtaining acknowledgment from the subject for the warning issued to the subject by any filter in the second plurality of filters;
• and
• e) proceeding with a fulfillment process when (i) no filter in the first plurality of filters has been fired and (ii) the subject has acknowledged each warning associated with each filter in the second plurality of filters that was fired, wherein the fulfillment process comprises:
• storing an indication in a subject profile of an initial order for the angiotensin II receptor blocker pharmaceutical composition,
• communicating an over the counter drug facts label for the angiotensin II receptor blocker pharmaceutical composition to the subject, and
• authorizing, upon confirmation from the subject that the over the counter drug facts label has been received and read, provision of the angiotensin II receptor blocker pharmaceutical composition to the subject;
• and
• wherein the angiotensin II receptor blocker pharmaceutical composition is administered to the subject after provision of the angiotensin II receptor blocker pharmaceutical composition has been authorized for the subject.